Project PXD001020

PRIDE Assigned Tags:
Biomedical Dataset
Download Project Files
Project Protein Table
Project Peptide Table
Visualize in PRIDE Inspector
Follow the next three steps to open your selected project or assay in PRIDE Inspector:

  • 1.

    Download, uncompress and open PRIDE Inspector
  • 2.

    Click in the magnifier on the left top corner, paste the project or assay that you would like to open in the search box, and hit search
  • 3.

    Click in the corresponding "Download" button to download the files and visualize them

Summary

Title

Redox-state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis

Description

In an endotoxaemic mouse model of sepsis, a tissue-based proteomics approach for biomarker discovery identified long pentraxin 3 (PTX3) as the lead candidate for inflamed myocardium. PTX3 accumulated as an octamer due to disulphide-bond formation in heart, kidney and lung ?common organ dysfunctions seen in patients with sepsis. Oligomeric moieties of PTX3 were also detectable in the circulation. The redox-state of PTX3 was quantified over the first 11 days in critically ill adult patients with sepsis. On admission day, there was no difference in the redox-state of PTX3 between survivors and non-survivors. From day 2 onwards, the conversion of octameric to monomeric PTX3 was consistently associated with a greater survival after 28 days of follow-up. For example, by day 2 post admission, octameric PTX3 was undetectable in survivors, but still constituted more than half of total PTX3 in non-survivors (P<0.001). Monomeric PTX3 was inversely associated with cardiac damage markers NT-proBNP, high sensitivity troponin I and T. In comparison to the conventional measurements of total PTX3 or NT-proBNP, the redox-sensitive oligomerization of PTX3 was more dynamic and a superior predictor of disease outcome.

Sample Processing Protocol

The Triton-insoluble fractions from control (n=4) and septic group (n=4) were denatured in Laemmli buffer at 97癈 for 5min. The proteins were separated by 5-20% gradient Tris-glycine gel at 5W for 45min then 30W for 4.5 hours. After electrophoresis, gels were stained using the PlusOne Silver staining Kit (GE Healthcare). Silver staining was used for band staining to avoid cross-contamination with fainter gel bands. All gel bands (n=48 per sample) were excised in identical parallel positions across lanes and no empty gel pieces were left behind. Subsequently, all gel bands were subjected to in-gel tryptic digestion using an Investigator ProGest (Digilab) robotic digestion system. Tryptic peptides were separated on a nanoflow LC system (Dionex Ultimate 3000, Thermo Fisher Scientific) using reversed phase columns (PepMap C18, 25cm x 75um) and eluted with a 40min gradient (10-25% B in 35 min, 25-40% B in 5min, 90% B in 10min, and 2% B in 20min, where A is 2% ACN, 0.1% formic acid in HPLC H2O and B is 90% ACN, 0.1% formic acid in HPLC H2O). Sequentially eluted peptides were directly analysed by tandem mass spectrometry (LTQ Orbitrap XL, Thermo Fisher Scientific) using full ion scan mode over the mass-to-charge (m/z) range 450-1600. Tandem MS (MS/MS) was performed on the top 6 ions using data-dependent mode with dynamic exclusion. Peak lists were generated by extract_msn_com.exe (version 5.0, Thermo Fisher Scientific) and searched against UniProt/SwissProt mouse database (version 2014_01, 16656 protein entries) using Mascot (version 2.3.01, Matrix Science). The mass tolerance was set at 30ppm for the precursor ions and at 0.8 Da for fragment ions. Carboxyamidomethylation of cysteine was used as a fixed modification and oxidation of methionine as a variable modification. Two missed cleavages were allowed.

Data Processing Protocol

Scaffold (version 4.3.0, Proteome Software Inc., Portland, OR) was used to calculate the normalized spectral counts and to validate peptide and protein identifications. According to the default values in the Scaffold software, peptide identifications were accepted if they could be established at greater than 95% probability as specified by the Peptide Prophet algorithm. Only tryptic peptides were included in the analysis. Protein identifications were accepted if they could be established at greater than 99% probability with at least two independent peptides. Proteomic differential expression was assessed using the normalized spectral abundance factor - power law global error model (NSAF-PLGEM). The Normalized Spectral Abundance Factor was calculated for each protein detected. Spectral count values of 0 were replaced by an empirically derived fractional value. The value was calculated to be the smallest value between 0 and 1, which provided the best fit to a normal distribution, as dertermined by a Shapiro-Wilks test. The NASF values were fit to a power-law global error model; differentially expressed proteins were then identified through a signal-to-noise (STN) test statistic. Proteins, which did not have a sufficient number of samples with spectra (less than 2 samples in each group) were removed prior to analysis.

Contact

Xiaoke Yin, Cardiovascular Division, King's College London
Manuel Mayr, King's British Heart Foundation Centre, King's College London, UK ( lab head )

Submission Date

29/05/2014

Publication Date

01/07/2014

Publication

    Cuello F, Shankar-Hari M, Mayr U, Yin X, Marshall M, Suna G, Willeit P, Langley SR, Jayawardhana T, Zeller T, Terblanche M, Shah AM, Mayr M. Redox-state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis. Mol Cell Proteomics. 2014 Jun 23. pii: mcp.M114.039446 PubMed: 24958171

Assay

Page 1 2 3 4 5 ... 39
Page size 10 20 50 100
Showing 1 - 10 of 384 results
# Accession Title Proteins Peptides Unique Peptides Spectra Identified Spectra View in Reactome
1 37399 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 1 32 90 45 648 68
2 37398 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 2 70 188 87 878 147
3 37397 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 3 73 245 112 1184 209
4 37396 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 4 79 235 118 1112 201
5 37395 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 5 75 290 141 1436 266
6 37292 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 6 111 443 207 1454 388
7 37394 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 7 101 425 180 1468 322
8 37291 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 8 105 501 193 1547 366
9 37393 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 9 97 404 193 1433 350
10 37290 gel-LC-MS/MS for LPS-induced sepsis in mouse heart - Control1 - Band 10 132 445 217 1423 386